OnMedica merges with MedSci
September 7, 2009Medical Communications, Sales and Marketing OnMedica, digi
Online PR company and medical education provider OnMedica Group has merged with medical communications company MedSci.The combined says it will …
Patients on Enbrel work longer, says study
September 7, 2009Research and Development, Sales and Marketing Enbrel, RA
Rheumatoid arthritis patients taking Enbrel are able to keep working for longer, according to a new study comparing its affects …
Blow for Irish pharma sector as Teva, Elan cut staff
September 7, 2009Manufacturing and Production Elan, Teva, lilly
Ireland’s pharmaceutical sector suffered a double blow last week as two drugmakers opted to make staff redundant at manufacturing plants …
NICE backs limited use of Lilly’s Plavix rival
September 7, 2009Research and Development Efient, NICE
NICE has recommended Lilly and Daiichi’s Efient for use on the NHS, giving the blood-thinner drug a boost in its …
Roche and PTC sign CNS research deal
September 4, 2009Research and Development CNS, Roche
PTC Therapeutics has signed an early-stage drug discovery deal with Roche that will focus on treatments for central nervous system …
Cameron: Tories are ‘the party of the NHS’
September 4, 2009NHS, US
David Cameron has called the Conservatives the "party of the NHS," in an attempt to reassure voters the service is …
Head-to-head boost for Brilinta over Plavix
September 4, 2009Research and Development, Sales and Marketing AZ, Brillinta
AstraZeneca has released details of its brand Brilinta’s performance in head-to-head trials with Plavix, the world’s second biggest-selling drug.Earlier this …
Roche’s MabThera expands licence in leukaemia
September 4, 2009Research and Development, Sales and Marketing MabThera, Roche
MabThera has been approved in Europe for use in previously treated chronic lymphocytic leukaemia, which Roche says will offer new …
Merck launches Saflutan in first European markets
September 4, 2009Research and Development, Sales and Marketing Merck, ophthalmology
Merck's glaucoma drug Saflutan has been launched in the UK and Spain. The manufacturer says more launches are planned in …
Novartis swine-flu jab effective in single dose
September 3, 2009Manufacturing and Production, Research and Development, Sales and Marketing Novartis, h1n1
A study of Novartis' pandemic swine-flu jab shows it is potentially protective after just one dose, which could help eke …
Pharmafocus expands into Europe
September 3, 2009Research and Development, Sales and Marketing Europe
The September issue of Pharmafocus marks a new stage in the publication’s development with an expanded monthly circulation that takes …
Merck unveils post-merger leadership team
September 3, 2009Research and Development, Sales and Marketing MA, Merck
The make-up of Merck and Schering-Plough's new corporate entity became clearer this week. Referred to as the 'new Merck' and …
Pfizer shamed with $2.3bn fine for marketing fraud
September 3, 2009Sales and Marketing Pfizer, US, illegal, off label prescribing
The US government has imposed a $2.3 billion fine on Pfizer for a string of offences including illegal off-label prescribing …
New cancer cases set to hit 17 million by 2020
September 2, 2009Research and Development, Sales and Marketing Cancer, healthcare
The next ten years will see a 30% leap in the number of new cancer cases across the world, according …
Pandemic planning: GSK’s Dr Neil Formica
September 1, 2009Research and Development GlaxoSmithKline, Vaccine, h1n1
UCB and Novartis expand alliance in Germany
September 1, 2009Sales and Marketing Germany, Novartis, UCB
UCB and Novartis have extended their partnership in Germany with a new licensing deal for the cardiovascular and diabetes drug …
Shire goes for early approval in Gaucher disease
September 1, 2009Research and Development, Sales and Marketing Gaucher's, Shire
Shire has filed for early US approval of its Gaucher disease drug velaglucerase alfa, as supplies to Genzyme's established rival …
Pradaxa data boosts Boehringer
September 1, 2009Research and Development, Sales and Marketing Boehringer, Pradaxa
Boehringer Ingelheim has unveiled new positive data for its blood-thinner Pradaxa, showing it reduces the risk of stroke compared to …
Pfizer agrees price cut in Clinton deal
September 1, 2009Research and Development, Sales and Marketing HIV, Pfizer, price cuts
Former US President Bill Clinton has brokered major new deals with Pfizer and Mylan to cut the price of tuberculosis …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
